Begin main content

Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details

Project Number pCODR 10151
Brand Name Xalkori
Generic Name Crizotinib
Strength 200 mg & 250 mg
Tumour Type Lung
Indication ROS1-positive advanced Non-Small Cell Lung Cancer
Funding Request As a single agent as first-line treatment for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC)
Review Status Under Review
Pre Noc Submission No
NOC Date August 28, 2017
Manufacturer Pfizer Canada Inc.
Submitter Cancer Care Ontario Lung Cancer Drug Advisory Committee
Submission Date October 30, 2018
Submission Deemed Complete November 13, 2018
Submission Type New Indication
Prioritization Requested
Stakeholder Input Deadline ‡ November 13, 2018
Check-point meeting (target date) January 22, 2019
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.